drugset / Trial / NCT05449392
Topical Antibacterial Agents for Prevention of COVID-19
RandomizedParallel-groupDouble-blindPrevention
Summary
The primary objective of this study is to determine whether intranasal application of aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo control in healthy participants.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-09-22
- Completion
- 2023-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bacitracin | Unknown | 400 iu | Intranasal |
| Subject | Neomycin | Unknown | 3.5 mg | Intranasal |
| Subject | Polymyxin B | Peptide | 5000 iu | Intranasal |